Global Vasomotor Symptoms Treatment Market Report and Forecast 2025-2034

Global Vasomotor Symptoms Treatment Market Outlook

The vasomotor symptoms treatment market size was estimated to be worth USD 9.40 billion in 2024. Driven by the rise in the number of vasomotor symptoms cases, the market is expected to rise at a CAGR of 6.7% during the forecast period of 2025-2034 to attain a value of more than USD 16.87 billion by 2034.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Vasomotor Symptoms: Insights, Causes, Risk Factors, and Treatment

Vasomotor symptoms are the symptoms that occur during menopause due to the constriction of blood vessels. The common vasomotor symptoms include hot flashes, night sweats, and changes in blood pressure.

Vasomotor symptoms occur at menopause because of the substantial hormonal changes that can affect the blood pressure and temperature regulator of the body. The significant estrogen level decrease triggers the nervous system, making the patient restless.

Vasomotor symptoms are more prevalent in African Americans than in Asian Americans. Smoking and obesity further increase the chances of this disorder.

The management of vasomotor symptoms is done using medications. The first-line treatment includes the use of hormonal regulators and anti-depressant drugs. Several lifestyle remedies are also incorporated to manage vasomotor symptoms.

According to the vasomotor symptoms treatment market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Route of Administration

• Oral

• Parenteral
  • Intravenous
  • Subcutaneous
• Topical

Market Breakup by Type of Therapy

• Hormonal Therapies
  • Estrogen Replacement Therapies
  • Pregestational Therapies
• Non-Hormonal Therapies
  • Clonidine
  • Serotonin Reuptake Inhibitors
  • Gabapentin
• Others

Market Breakup by Distribution Channel

• Hospital Based Pharmacies

• Online Pharmacies

• Retail Pharmacies

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Vasomotor Symptoms Treatment Market Scenario

The rising prevalence of vasomotor symptoms, such as hot flashes and night sweats during menopausal phases, is anticipated to boost the market growth. According to the International Journal of Applied & Basic Medical Research, nearly 88% of women reported menopausal and vasomotor symptoms, thus facilitating the demand for more therapeutic options.

The increasing investments in the research and development activities by the key players are driving the treatment of the vasomotor symptoms treatment market development. This further contributes to the discovery of novel therapeutic interventions, that will propel the market expansion.

Additional factors, such as a rise in the adoption of a sedentary lifestyle, an increase in the number of mergers and acquisitions, and raising awareness regarding vasomotor symptoms are attributing to the growth of the market.

Regional Insights

North America is anticipated to account for the largest revenue share of the global market. This is due to the high incidence of post-menopausal symptoms, raising awareness about women’s health, and increasing expenditure in the healthcare sector. The significant presence of key global players in this region is also projected to boost the market growth.

During the forecast period, Latin America is expected to witness the fastest growth in the vasomotor symptoms treatment market. The factors leading to this rapid growth include the rising awareness regarding menopausal symptoms and more significant expenditure in the research and development sector.

Therapeutic Landscape

There are several therapeutic interventions for the management of vasomotor symptoms. The procedures used for the treatment of vasomotor symptoms are pharmacological and non-pharmacological. In pharmacological ones, there are two main primary therapies, hormonal replacement therapy (HRT) and non-hormonal medications.

Standard Therapies: Hormonal and Non-Hormonal Therapeutic Interventions

During menopause, there is a substantial reduction in the levels of oestrogen and progesterone. Hormonal replacement therapies are generally utilised to restore reduced hormonal levels, which will subsequently help regulate average body temperature. There are two hormone replacement therapies, oestrogen therapy and oestrogen progesterone hormone therapy.

Hormonal replacement therapies have associated adverse effects; therefore, there is a shift toward non-hormonal medications. Different medications can be incorporated into the treatment regimen depending on the vasomotor symptoms. Serotonin reuptake inhibitors, such as citalopram and fluoxetine, are generally used for hot flashes.

Other medications, such as antidepressants, anti-seizure, urinary, blood pressure, and over-the-counter drugs, also help alleviate vasomotor symptoms.

Alternative treatments, including acupuncture, hypnosis, meditation, and relaxation techniques, have been beneficial for managing menopausal and vasomotor symptoms.

Clinical Trial Landscape

The currently available therapies are associated with several adverse effects and thus leading to several other diseases and comorbidities. Hence, scientists are performing clinical trials for novel therapeutic interventions that will be more effective and have fewer side effects.

Emerging Therapies: Discovery of Novel Medications

M2S Hot Flash Study, an ongoing clinical trial by Fervent Pharmaceuticals, is being performed to manage vasomotor symptoms. This virtual Phase II clinical trial treats moderate night sweats and hot flashes. The primary objective is to analyse the safety and efficacy of peri and post-menopausal therapy.

Astellas Pharma, a key player, is performing a SKYLIGHT 4 clinical trial study to assess the safety and efficacy of fezolinetant, a non-hormonal therapy. Phase III trials are under process for testing the safety and tolerability of this investigational selective neurokinin three receptor antagonist on endometrial health.

Another set of clinical trials is undergoing for the novel neurokinin three receptor antagonist, which is anticipated to provide the potential treatment for managing vasomotor symptoms. Acer Therapeutics is conducting Phase II clinical trials for its ACER-801 (osanetant) drug, and if successfully approved can benefit in the alleviation of vasomotor symptoms.

With the increasing number of key players, there is a rise in the number of drugs under the pipeline. These novel products' approval and launch are expected to boost the market growth.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the vasomotor symptoms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Bayer AG

• Fervent Pharmaceuticals, LLC

• Astellas Pharma Inc.

• Frazier Healthcare Partners

• Mitsubishi Tanabe Pharma Corporation

• Eli Lilly and Company

• AbbVie Inc.

• AMAG Pharmaceuticals Inc.

• Emcure Pharmaceuticals Limited

• Merck & Co., Inc.

• Novartis AG

• Novo Nordisk A/S

• Pfizer Inc.

• Teva Pharmaceutical Industries Ltd.

Key Highlights of the Report